Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CORBF NASDAQ:DCGO NASDAQ:PIII NASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORBFGlobal Cord Blood$1.00+11.1%$0.94$0.25▼$1.75$109.40M-0.5989,383 shs3,587 shsDCGODocGo$1.53-2.5%$1.53$1.23▼$5.68$153.56M0.97342,326 shs421,979 shsPIIIP3 Health Partners$8.60-0.8%$7.30$5.80▼$26.99$62.34M0.827,174 shs1,771 shsXGNExagen$9.74-2.6%$8.70$2.38▼$10.34$220.04M1.6215,112 shs141,136 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORBFGlobal Cord Blood+11.11%-4.76%+81.82%-4.76%-33.33%DCGODocGo-2.55%-3.16%-11.56%+5.52%-56.78%PIIIP3 Health Partners-0.28%-1.94%+24.91%+33.56%-68.44%XGNExagen-2.60%+0.72%+0.72%+36.80%+221.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORBFGlobal Cord Blood$1.00+11.1%$0.94$0.25▼$1.75$109.40M-0.5989,383 shs3,587 shsDCGODocGo$1.53-2.5%$1.53$1.23▼$5.68$153.56M0.97342,326 shs421,979 shsPIIIP3 Health Partners$8.60-0.8%$7.30$5.80▼$26.99$62.34M0.827,174 shs1,771 shsXGNExagen$9.74-2.6%$8.70$2.38▼$10.34$220.04M1.6215,112 shs141,136 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORBFGlobal Cord Blood+11.11%-4.76%+81.82%-4.76%-33.33%DCGODocGo-2.55%-3.16%-11.56%+5.52%-56.78%PIIIP3 Health Partners-0.28%-1.94%+24.91%+33.56%-68.44%XGNExagen-2.60%+0.72%+0.72%+36.80%+221.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCORBFGlobal Cord Blood 0.00N/AN/AN/ADCGODocGo 2.50Moderate Buy$3.59134.64% UpsidePIIIP3 Health Partners 2.50Moderate Buy$16.2588.95% UpsideXGNExagen 3.13Buy$12.0023.20% UpsideCurrent Analyst Ratings BreakdownLatest PIII, XGN, DCGO, and CORBF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025XGNExagenB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.009/10/2025XGNExagenB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/28/2025PIIIP3 Health PartnersLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.008/21/2025DCGODocGoCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$1.45 ➝ $1.607/30/2025XGNExagenCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$10.007/30/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.007/30/2025XGNExagenKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSector Weight ➝ Overweight$12.007/23/2025XGNExagenCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCORBFGlobal Cord Blood$196.12M0.62$0.71 per share1.40N/A∞DCGODocGo$616.55M0.24$0.41 per share3.71$3.09 per share0.50PIIIP3 Health Partners$1.50B0.04N/AN/A$10.58 per share0.81XGNExagen$55.64M3.85N/AN/A$0.54 per share18.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/ADCGODocGo$19.99M-$0.19N/A19.13N/A-4.20%-3.26%-2.24%11/6/2025 (Estimated)PIIIP3 Health Partners-$135.85M-$46.01N/AN/AN/A-9.99%-183.60%-17.83%11/11/2025 (Estimated)XGNExagen-$15.11M-$0.89N/AN/AN/A-28.85%-130.38%-34.69%11/11/2025 (Estimated)Latest PIII, XGN, DCGO, and CORBF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PIIIP3 Health Partners-$3.29-$6.23-$2.94-$6.23$356.52 million$355.79 million8/7/2025Q2 2025DCGODocGo-$0.06-$0.11-$0.05-$0.11$77.58 million$80.42 million7/29/2025Q2 2025XGNExagen-$0.18-$0.18N/A-$0.21$16.25 million$17.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCORBFGlobal Cord BloodN/AN/AN/AN/AN/ADCGODocGoN/AN/AN/AN/AN/APIIIP3 Health PartnersN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCORBFGlobal Cord BloodN/AN/AN/ADCGODocGoN/A2.362.36PIIIP3 Health Partners2.290.310.31XGNExagen1.064.954.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCORBFGlobal Cord BloodN/ADCGODocGo56.44%PIIIP3 Health Partners7.75%XGNExagen75.25%Insider OwnershipCompanyInsider OwnershipCORBFGlobal Cord Blood0.50%DCGODocGo3.80%PIIIP3 Health Partners17.79%XGNExagen12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableDCGODocGo4,40797.81 million94.09 millionOptionablePIIIP3 Health Partners5007.19 million5.91 millionNot OptionableXGNExagen22022.00 million19.23 millionOptionablePIII, XGN, DCGO, and CORBF HeadlinesRecent News About These CompaniesExagen (NASDAQ:XGN) Earns Buy Rating from Analysts at B. Riley1 hour ago | americanbankingnews.comExagen (NASDAQ:XGN) Upgraded to "Strong-Buy" at B. Riley2 hours ago | americanbankingnews.comB. Riley Securities Initiates Coverage of Exagen (XGN) with Buy RecommendationSeptember 12 at 12:58 PM | msn.comExagen Inc. (NASDAQ:XGN) Receives Average Recommendation of "Buy" from AnalystsSeptember 12 at 2:40 AM | marketbeat.comExagen initiated with a Buy at B. RileySeptember 11 at 12:26 PM | msn.comBeyond The Numbers: 4 Analysts Discuss Exagen StockSeptember 11 at 12:26 PM | benzinga.comExagen Inc. (NASDAQ:XGN) Short Interest UpdateSeptember 6, 2025 | marketbeat.comStonepine Capital Management LLC Sells 155,302 Shares of Exagen Inc. $XGNAugust 26, 2025 | marketbeat.comShort Interest in Exagen Inc. (NASDAQ:XGN) Expands By 52.8%August 20, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Buy" by BrokeragesAugust 18, 2025 | marketbeat.comExagen Inc. to Participate in Third Quarter Investor ConferencesAugust 6, 2025 | gurufocus.comExagen Inc. to Participate in Third Quarter Investor ConferencesAugust 6, 2025 | globenewswire.comBTIG Sticks to Their Buy Rating for Exagen (XGN)August 2, 2025 | theglobeandmail.comExagen (XGN) Receives a Buy from Craig-HallumAugust 1, 2025 | theglobeandmail.comExagen Inc. Reports Record Revenue Amidst Growth ChallengesAugust 1, 2025 | theglobeandmail.comCanaccord Genuity Sticks to Its Buy Rating for Exagen (XGN)July 31, 2025 | theglobeandmail.comXGN | Exagen Inc. Annual Cash Flow Statement | MarketWatchJuly 31, 2025 | marketwatch.comKeybanc Upgrades Exagen (XGN)July 31, 2025 | msn.comExagen upgraded to Overweight from Sector Weight at KeyBancJuly 30, 2025 | msn.comExagen Q2 Revenue Jumps 14 PercentJuly 29, 2025 | aol.comAExagen Inc. (XGN) Q2 2025 Earnings Call TranscriptJuly 29, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePIII, XGN, DCGO, and CORBF Company DescriptionsGlobal Cord Blood NYSE:CORBF$1.00 +0.10 (+11.11%) As of 09/12/2025 10:20 AM EasternGlobal Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.DocGo NASDAQ:DCGO$1.53 -0.04 (-2.55%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.50 -0.03 (-1.63%) As of 09/12/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.P3 Health Partners NASDAQ:PIII$8.60 -0.07 (-0.81%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$8.56 -0.04 (-0.41%) As of 09/12/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.Exagen NASDAQ:XGN$9.74 -0.26 (-2.60%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$10.00 +0.26 (+2.67%) As of 09/12/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
